Benchmark xt device

Manufactured by Roche

Sourced in France

The Benchmark XT device is a laboratory equipment product manufactured by Roche. It is designed to perform specific tasks within a laboratory setting. The core function of the Benchmark XT device is to facilitate various analytical processes, but a detailed description of its intended use or capabilities is not available at this time.

Automatically generated - may contain errors

Lab products found in correlation

Cell recovery solution, by Corning (1 mentions) Anti p53, by Agilent Technologies (1 mentions) Anti atrx, by Merck Group (1 mentions) Hla abc, by Abcam (1 mentions) Hep par 1, by Roche (1 mentions) Sstr2, by Abcam (1 mentions) Dispase 2, by Merck Group (1 mentions) Histogel, by Thermo Fisher Scientific (1 mentions) Pd l1, by Roche (1 mentions) Pan trk, by Abcam (1 mentions)

Spelling variants of this product

BenchMark XT (769 citations) BenchMark device (2 citations) Ventana Benchmark XT device (2 citations)

5 protocols using benchmark xt device

Histopathological Characterization of Liver Tumor Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

Liver biopsies from tumoral and non-tumor tissue, as well as tumor organoid xenografts, were fixed in 4% phosphate-buffered formalin and embedded in paraffin using standard procedures. Additional biopsies were also embedded in O.C.T. (Tissue-Tek) and frozen using standard procedures. Tumor organoids were released from BME2 by incubating in Cell Recovery Solution (Corning) following the manufacturer’s instructions. Organoids were then fixed in freshly prepared 4% formalin solution in PBS for 30 min at room temperature following dehydration and paraffin embedding. Sections were subjected to H&E, Masson’s trichrome, Alcian blue-periodic acid-Schiff (PAS), as well as immunohistochemical staining, using standard procedures. Histopathological evaluation was assessed by two board-certified pathologists (M.S.M. and L.M.T.). Tumors were classified based on architecture and cytological features, and graded according to the Edmondson grading system (Edmondson and Steiner, 1954 (link)).
For immunohistochemistry, the following primary antibodies were used for automated staining on a Benchmark XT device (Ventana Medical Systems): AFP (Ventana catalog number [Cat. No.] 760-2603), GS (Ventana Cat. No. 760-4898), GPC3 (Ventana Cat. No. 790-4564), HSP70 (Biocare Medical CM407A), Keratin 7 (Ventana Cat. No. 790-4462), Keratin 19 (Ventana Cat. No. 760-4281), and KI-67 (Ventana Cat. No. 760-4286).

Nuciforo S., Fofana I., Matter M.S., Blumer T., Calabrese D., Boldanova T., Piscuoglio S., Wieland S., Ringnalda F., Schwank G., Terracciano L.M., Ng C.K, & Heim M.H. (2018). Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies. Cell Reports, 24(5), 1363-1376.

+ Open protocol

+ Expand

Pan-TRK Immunohistochemistry for TrkA/B/C

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC was performed on 4 μm paraffin‐embedded whole tissue sections for each case. Pan‐TRK immunohistochemical staining for TrkA/B/C expression was performed using Ventana pan‐TRK antibody (clone EPR17341; #790‐7026, ready to use, Ventana Medical Systems, Tucson, AZ, USA), a rabbit recombinant monoclonal antibody reactive to a C‐terminal epitope conserved across TRK‐A, ‐B, and ‐C proteins and present in both wild type and chimeric proteins. All assays were performed on a fully automated BenchMark XT device (Ventana Medical Systems). Ganglia of the submucosal plexus of a normal vermiform appendix and an infantile fibrosarcoma with known ETV6‐NTRK3 fusion were used as positive controls and were run simultaneously with each sample. Lymphocytes served as internal negative controls. Tumors were considered positive if ≥1% of tumor cells exhibited positivity at any intensity above background. Different subcellular staining patterns were considered positive, as previously suggested (cytoplasmic, membranous, nuclear, and perinuclear) [8 (link), 13 (link), 14 (link)]. Signal intensity was expressed as a score, from 1 to 3, corresponding to weak, moderate, and strong signals. Two independent observers carried out immunohistochemical analysis, and both observers were blinded; in discordant cases, a consensus was reached by collegial discussion.

Zito Marino F., Buono S., Montella M., Giannatiempo R., Messina F., Casaretta G., Arpino G., Vita G., Fiorentino F., Insabato L., Sgambato A., Orditura M., Franco R, & Accardo M. (2023). NTRK gene aberrations in triple‐negative breast cancer: detection challenges using IHC, FISH, RT‐PCR, and NGS. The Journal of Pathology: Clinical Research, 9(5), 367-377.

+ Open protocol

+ Expand

Immunohistochemical Analysis of ATRX, p53, and CCND1

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed on 4-μm-thick sections of formalin-fixed paraffin embedded blocks with a ventana Benchmark XT Device. The following antibodies were used after antigen retrieval to assess ATRX (anti-ATRX, Sigma, polyclonal, dilution 1/400), p53 (anti-p53, Dako clone DO.7, dilution 1/200) and CCND1 (anti-CCND1, Ventana, clone SP4). p53 protein was defined as ‘highly expressed’ when we observed a strong nuclear expression in more than 10% of the nuclei.

Kamoun A., Idbaih A., Dehais C., Elarouci N., Carpentier C., Letouzé E., Colin C., Mokhtari K., Jouvet A., Uro-Coste E., Martin-Duverneuil N., Sanson M., Delattre J.Y., Figarella-Branger D., de Reyniès A, & Ducray F. (2016). Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. Nature Communications, 7, 11263.

+ Open protocol

+ Expand

Histopathological Evaluation of Tumor Organoids

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tumor and liver tissues were fixed in 4% phosphate-buffered formalin and embedded in paraffin using standard procedures. Tumor organoids were released from BME2 by incubation in Dispase II (Sigma-Aldrich, Cat. No. D4693). Organoids were fixed in 4% phosphate-buffered formalin in PBS for 30 min at room temperature following encapsulation in HistoGel (Thermo Fisher Scientific, Cat. No. HG-4000-012) and subsequent dehydration and paraffin embedding.
Histopathological evaluation was assessed by three board-certified pathologists (MSM, JV and LMT). Tumors were classified based on architecture and cytological features, and graded according to the Edmondson grading system^{10 (link),11}. The following primary antibodies were used for automated diagnostic immunohistochemical staining on a Benchmark XT device (Ventana Medical Systems) at the Institute of Pathology of the University of Basel: AFP (Ventana, Ref-Nr. 760-2603), ARG1 (Ventana, Ref-Nr. 760-4801), CD10 (Ventana, Ref-Nr. 790-4506), CD56 (Ventana, Ref-Nr. 790-4465), CHGA (Ventana, Ref-Nr. 760-2519), GPC3 (Ventana, Ref-Nr. 790-4564), HLA-ABC (Abcam, Cat. No. ab70328), Hep Par-1 (Ventana, Ref-Nr. 760-4350), KRT19 (Ventana, Ref-Nr. 760-4281), Ki-67 (Dako, Cat. No. IR626), Pan-TRK (Abcam, Cat. No. ab181560), PD-L1 (Ventana, Ref-Nr. 740-4907), SYP (Ventana, Ref-Nr. 790-4407), and SSTR2 (Abcam, Cat. No. ab134152).

Meier M.A., Nuciforo S., Coto-Llerena M., Gallon J., Matter M.S., Ercan C., Vosbeck J., Terracciano L.M., Soysal S.D., Boll D., Kollmar O., Delaloye R., Piscuoglio S, & Heim M.H. (2022). Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report. Communications Medicine, 2, 80.

+ Open protocol

+ Expand

Automated Immunohistochemical Analysis of Lung Cancer Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Automated procedures were assessed (Charpin et al, 2009a (link), 2009b (link)) on a Ventana Benchmark XT device, using E-view detection Ventana kits for DAB staining and the following specific monoclonal mouse or rabbit antibodies: monoclonal anti-savage EGFR clone 3C6 (Ventana Roche, Meylan Grenoble, France); clone B6 for detection of the E746- A750 exon 19 deletion of the EGFR gene (Cell Signaling Technology, St. Quentin, France); clone 43B2 for L858R, for the detection of mutated EGFR exon 21 (Cell Signaling Technology); anti-ALK clone 5A4 (Abcam, Paris, France) for the detection of the fusion transcript echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK); clone SP1 anti-ER (Ventana Roche); clone 1E2 anti PR (Ventana Roche); and clone 4B5 anti-HER-2 (Ventana Roche). The slides were counterstained with hematoxylin and bluing reagent.
The positive controls for mutated or amplified non-EGFR consisted of paraffin sections of breast and qPCR-amplified colonic carcinomas, whereas the controls for mutated EGFR and translocated ALK consisted of paraffin sections of mutated EGFR (exon 19 deletion and exon 21 mutation) or FISH EML4-ALK-translocated lung carcinomas.

Secq V., Villeret J., Fina F., Carmassi M., Carcopino X., Garcia S., Metellus I., Boubli L., Iovanna J, & Charpin C. (2014). Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations. British Journal of Cancer, 110(4), 1045-1052.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!